July 10, 2017 An article describing the formation of the HNCIG as well as its objectives, structure, and activities was published in Oral...

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK July 15, 2020...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED...

January 28, 2021 This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or...

April 2021 Taxane-based TPEx regimen appears to be a new option in first line recurrent/metastatic HNSCC, with a shorter time on therapy...

February 2023 This multicentre individual patient data analysis aimed to identify the extent of discordance and its prognostic...

HNCIG PUBLISHES INTERNATIONAL CONSENSUS GUIDELINES FOR HEAD AND NECK SURGICAL ONCOLOGY PRACTICE IN TIMES OF SEVERE RESOURCE CONSTRAINT...

January 5, 2019 On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based...

June 14, 2018 A number of abstracts related to the HNCIG appeared at this year’s ASCO General Meeting in Chicago. First, those related to...

October 22, 2019 Dysphagia is one of the most serious and common adverse events after curative-intent treatment for HNSCC, with huge QOL...

INTERGROUP CONSENSUS GUIDELINES ON CTV-P DELINEATION IN LARYNGEAL, HYPOPHARYNGEAL, OROPHARYNGEAL, AND ORAL CAVITY SQUAMOUS CELL...

PUBLICATION OF AN INTERNATIONAL GUIDELINE FOR THE DELINEATION OF THE CLINICAL TARGET VOLUMES (CTV) FOR NASOPHARYNGEAL CARCINOMA January...